You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Implantable Peripheral Nerve Stimulator for Treatment of Phantom Limb Pain

    SBC: Ripple, LLC            Topic: 999

    Abstract Chronic phantom limb painPLPhas been reported to inflict as many asof people with amputationsPLP is described as feeling like burningtwistingitchingor pressure in part of the missing limbThese painful sensations have a substantial negative impact on quality of lifepeople who suffer PLP have high rates of depressiondifficulty sleepingregular absences from workdissociation with family frien ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Generalizing and Standardizing fMRI Tools for Differentiating Mental Illnesses and Predicting Medication-Class Response in Patients

    SBC: ADVANCED BIOMEDICAL INFORMATICS GROUP, L.L.C.            Topic: 102

    Project Summary/AbstractMood disorders, like many psychiatric conditions, have their onset in emerging adulthood and often last a lifetime. Mental illnesses have an excessively large loading of Disability Adjusted Life Years, making early intervention crucial for both individuals and society. Differentiating bipolar disorder (BD) from major depressive disorder (MDD) based on the Diagnostic and Sta ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  3. Vaccination against Zika virus infection using mosquito NeSt1 protein

    SBC: L2 Diagnostics, LLC            Topic: NIAID

    Arthropod-borne viruses (arboviruses) present a substantial threat to human and animal health worldwide. They are transmitted by hematophagous arthropods, in which mosquitoes are one of the main transmitters. The mosquito specie, Aedes aegypti, is the primary mosquito vector of several widely spread arboviruses as zika, dengue or West Nile viruses. Mosquitoes transmit these pathogens by inoculatin ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  4. Clinical Optimization of Ultrasonic Drug Delivery Technologies for Underserved Minority US Veterans in Chronic Pain

    SBC: Zetroz Systems LLC            Topic: NIMHD

    Project Summary: Narcotic use in pain management of underserved minority populations and minority United States veterans has played a major role in the ongoing opioid crisis. According to the NIH, veterans are more susceptible to opioid addiction and are 40% more likely to suffer from severe chronic joint pain then non-veterans. Over the next decade, the percentage of minority veterans will increa ...

    SBIR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  5. Multiplexed Bioassay for Checkpoint Inhibitor Autoimmunity

    SBC: L2 Diagnostics, LLC            Topic: NIAID

    The advent of checkpoint inhibitor (CPI) therapy in human cancer has dramatically changed the landscape of treatment strategies in recent years. Previously, cancers with largely ineffective therapeutics and a poor prognosis, such as melanoma, have experienced significant advances of patients able to extend survival and/or progression free disease. Within the tumor microenvironment, a number of imm ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  6. Portable Liquid Chromatography Platform for Diverse Pharmaceutical Applications

    SBC: Axcend, LLC            Topic: 400

    Project Summary Liquid chromatography (LC) is the most important analytical technique in the pharmaceutical industry. Currently available LC instruments on the market suffer from high cost and large size, contrary to the general trend of miniaturization within the field of analytical instrumentation. Axcend Corporation has developed a compact LC platform weighing 7 kg while still maintaining simil ...

    SBIR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  7. Developing Drug-like Small Molecules that Target Toxic Repeat RNAs to Alleviate Myotonic Dystrophy Type 1-derived Mis-Splicing

    SBC: Nymirum, Inc.            Topic: 104

    Project Summary Abstract Nymirum will utilize its technology platform to identify and optimize a drug-like, orally available small molecule that binds toxic CUG repeat RNAs to rescue myotonic dystrophy type 1 (DM1) derived mis-splicing and treat the disease. DM1 is a rare genetic disorder that leads to progressive muscle degeneration, cardiovascular disease, severe cognitive disabilities, insulin ...

    SBIR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  8. Photo-mediated ultrasound therapy for treatment of cutaneous vascular malformations

    SBC: Photosonox LLC            Topic: NIBIB

    ABSTRACT: Cutaneous vascular malformations (CVM), such as port wine stain (PWS) which occurs in 0.3–0.5% of newborns, are often a cause of great concern to patients for both medical and cosmetic reasons. Laser irradiation with flashlamp-pumped pulsed dye lasers, i.e. photothermolysis therapy (PTT), is currently the gold standard treatment for PWS. Most patients with PWS, however, fail to clear c ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  9. Therapeutics for Huntington's Disease

    SBC: Synthetic Biodesign, LLC            Topic: 999

    Huntington’s disease is a devastating neurodegenerative disease with no current therapeutic options. The proposed work will identify novel therapeutic leads for development as badly needed new drugs in phase II studies. This will be achieved using a novel natural products-based approach.Natural products or their derivatives have accounted for most of our current drugs, demonstrating their unique ...

    SBIR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  10. Demonstrating the feasibility of CCG-257081 as a preventive therapy to inhibit bleomycin-induced lung fibrosis in mice

    SBC: FIBROSIX INC.            Topic: 102

    ABSTRACT Front-line therapy for patients diagnosed with Hodgkin’s lymphoma or germ cell cancers includes the drug bleomycin, a highly effective agent with a debilitating side effect. About 10-12% of bleomycin-treated patients develop pneumonitis with progression to pulmonary fibrosis during therapy as a direct result of bleomycin. An estimated 10-20% of these cases are fatal. The current standar ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government